2685
Each subject was treated according to the following sequence: baseline; phase 1 (days 1-6): cisapride 10 mg 4 times/day; washout (days 7-13); phase 2 (days 14-44): fluoxetine 20 mg/day; and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52).
 ( potential therapeutic event: treated ,  Each subject: Subject, baseline; phase 1 (days 1-6): cisapride 10 mg 4 times/day; washout (days 7-13); phase 2 (days 14-44): fluoxetine 20 mg/day; and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52): Treatment, cisapride: Treatment.Drug, fluoxetine: Treatment.Drug, cisapride: Treatment.Drug, fluoxetine: Treatment.Drug, 10 mg: Treatment.Dosage, 20 mg/day: Treatment.Dosage, 10 mg: Treatment.Dosage, 20 mg/day: Treatment.Dosage, 4 times/day: Treatment.Freq, 4 times/day: Treatment.Freq, cisapride: Combination.Drug, fluoxetine: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: treated ,  Each subject: Subject, baseline; phase 1 (days 1-6): cisapride 10 mg 4 times/day; washout (days 7-13); phase 2 (days 14-44): fluoxetine 20 mg/day; and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52): Treatment, cisapride: Treatment.Drug, fluoxetine: Treatment.Drug, cisapride: Treatment.Drug, fluoxetine: Treatment.Drug, 10 mg: Treatment.Dosage, 20 mg/day: Treatment.Dosage, 10 mg: Treatment.Dosage, 20 mg/day: Treatment.Dosage, 4 times/day: Treatment.Freq, 4 times/day: Treatment.Freq, cisapride: Combination.Drug, fluoxetine: Combination.Drug) 